International Trial of Selumetinib in Combination With Dexamethasone for the Treatment of Acute Lymphoblastic Leukaemia
Status:
Recruiting
Trial end date:
2022-05-01
Target enrollment:
Participant gender:
Summary
This trial is to investigate the combination of selumetinib and dexamethasone in the
treatment of acute lymphoblastic leukaemia (ALL) in both adults and children. Phase I is to
find the most suitable dose of selumetinib to safely give with dexamethasone. Phase II will
use this dose to find out how well the combination works.